Niagen Bioscience Reports Clinical Trial Shows Niagen Supplement Boosts NAD+ and Eases Long COVID Symptoms
Niagen Bioscience Inc. has reported results from a randomized controlled trial of its Niagen® supplement for long COVID. The study, published in The Lancet’s eClinicalMedicine, showed that daily Niagen supplementation significantly increased NAD+ levels and improved executive functioning, fatigue, depression, and sleep quality in 58 non-hospitalized adults over 24 weeks. The findings have been presented, highlighting the potential benefits of Niagen for those suffering from persistent COVID-19 symptoms.
Niagen Bioscience Inc. has announced results from the first-ever randomized controlled trial examining Niagen®, the company’s patented nicotinamide riboside (NR) supplement, in individuals with long COVID. The findings, published in The Lancet’s eClinicalMedicine journal, indicate that daily supplementation with Niagen significantly increased NAD+ levels and was associated with within-group improvements in executive functioning, fatigue, depression, and sleep quality compared to baseline. The 24-week, double-blind, placebo-controlled study involved 58 non-hospitalized adults experiencing persistent symptoms following COVID-19 infection. Results from this clinical trial have already been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112992378) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
